ERBB2 and neoplasm: Extrapolation of the benefits demonstrated in the adjuvant Trastuzumab trials and evidence from small case series of HER2+ patients with T1aN0 and T1bN0 tumours suggest there may be a similar relative benefit from biological therapies regardless of stage and nodal status, indicating that if the worse survival of these tumours is correct there would be a significant absolute benefit from treating these patients with adjuvant Trastuzumab (Banerjee and Smith, 2010; Rodrigues et al, 2010).